Janssen in Belgium is part of the worldwide Pharmaceutical Group, since several years known as Janssen Pharmaceutical Companies of Johnson & Johnson. The group employs a total of more than 40,000 people in 150 countries. Its core activities are the creation, development and delivery of therapeutic solutions to a host of medical needs that are as yet inadequately met.
Today, Janssen is one of the most innovative pharmaceutical companies in the world. The company chooses to develop treatments for some of the most serious disorders and complex medical challenges of our time, including diabetes, hepatitis, HIV, cancer, arthritis, dementia and other mental disorders.
The patient is the top priority for all Janssen employees
Our parent company, Johnson & Johnson, discovers and develops, manufactures and sells a wide range of medicines, consumer products, medical devices and diagnostics, all of which make a daily difference in the health of people all over the world. The central focus of Our Credo is our responsibility to the patients. Janssen's ethical code shines like a beacon for all 128,000 Johnson & Johnson employees in 60 countries.
The various areas of expertise of Janssen Belgium are organized in distinct legal entities: Janssen Pharmaceutica NV, Janssen Infectious Diseases-Diagnostics BVBA, Janssen-Cilag NV and J.C. General Services CVBA. Throughout this report, these entities are collectively referred to as the Janssen Campus.
The company has established locations in Beerse (Beerse I and II), Geel, Olen, Diegem, La Louvière, Courcelles and Merksem and employs approximately 4500 employees. Together, these organizations discover, develop and manufacture medicines and therapeutic solutions for patients across the globe. Our work ranges from the very inception of an idea for a solution - the basic research into new medicines - through the production, commercial and supporting services all the way to the distribution of the medicines. As a result, Janssen in Belgium has the complete pharmaceutical cycle in its own hands, which makes the company unique within the world of pharmaceuticals.
Janssen in Belgium sets the tone in the area of Research & Development. The campus here is the largest Research & Development (R&D) center for small molecules within the entire world-wide Janssen Group. In Belgium alone, the R&D center employs some 1800 people. The R&D activities are directed at five strategic disease domains, and the company collaborates with various internal and external partners to augment and accelerate this innovation.
Janssen in Belgium possesses extensive expertise in the areas of neuroscience, oncology and infectious diseases. Daily, the company and its partners focus their efforts on the discovery and development of a new generation of small molecules in the domains of schizophrenia, depression, pain management, dementia, hepatitis, HIV and various types of cancer. The organization practices precision medicine and alters disease research by investing in first-class research competencies.
Within the Johnson & Johnson Group, the production site in Geel is a leader in the area of chemical production and development. At the campus in Beerse, the focus is on high-quality final products for patients and consumers. It is here that the production for a good number of Johnson & Johnson companies takes place. Thanks to a strategic approach, solid processes and increasing volumes, this site looks confidently forward to a bright future.
Janssen strives for the discovery of solutions, solutions that will be a breakthrough in the treatment of disease and solutions that mean added value for the patients, the national health services and the government. The future solutions go further than the traditional treatments that we know today. Janssen is now laying the groundwork for more comprehensive patient care systems and for a new care model for the prevention, diagnosis, treatment and follow-up of diseases. The patient and his or her personal needs are the central focus of this shift.
Janssen strives for the discovery of solutions, solutions that will be a breakthrough in the treatment of disease and solutions that mean added value
Janssen wants to provide people with access to health care solutions but also wants their products to be used in the best possible way throughout the entire treatment period. To do this successfully, quite a bit is required: education to raise awareness of a disease, services and support to help patients to use their medicines correctly, new commercialization strategies or even methods to help predict or prevent a disease.
A great deal of scientific progress has already occurred, but the company does not underestimate how great the challenge is and how much research is still left to be done. The medical challenges of today are more complex than ever before. Science and technology evolve so quickly that it is only possible to make a difference if you work together with other parties intensively and over the long-term. That is the reason that Janssen does not limit its search for new medicines to within its own four walls. On the contrary, Janssen considers the whole world its laboratory. The experts collaborate with external parties within an open-innovation model and at every stage of the value chain - from the early discovery to the commercialization stage. They search for medical breakthroughs wherever they take place – whether at a university, a research institution or even in other pharmaceutical or biotechnology companies. Janssen aims to identify the best ideas both inside and outside of the organization and to use them to tackle the greatest unanswered medical needs of our time.
Janssen contributes to making the world a better place by improving health and wellness. But also by handling our planet with care, by acting in a responsible manner every day and by strengthening the company, so that it is able to continue to provide essential contributions to global health care and to the Belgian economy. The company accepts this responsibility and calls on all stakeholders to prepare together for a future of accessible, sustainable and affordable health care.
- Discovery Research
- Advanced Technologies
- Early and Late Development
- Scientific Drug Safety
- Chemical and Pharmaceutical Development
- Clinical Research
- Clinical Supply Unit
- Clinical Pharmacology
- Clinical Data Management
- Regulatory Affairs
- Commercial Development
- Program Management
- Chemical Production
- Pharmaceutical Production
- Global Quality Groups
- Customer Logistics Services
- Packaging & Distribution
- Worldwide Engineering & Technical Operations
- Janssen Commercial EMEA
- Janssen-Cilag NV
- Trade Development
- Strategic Marketing & Medical Affairs, Health Economics and Pricing Policy
- Corporate Functions
- Legal Department/Patents
- Information Technology
- Procurement / Adminstration
- Environment, Health and Safety (Prevention)
- General & Technical Services
- Human Resources
- Campus Communications Department
- Research & Development Infectious Diseases
- Diagnostic Solutions
- HIV Resistance Tests
The research organization in Beerse, together with research centers in other European countries and the US, has been incorporated into a single global organization, focusing on five core research fields: neurosciences, infectious diseases and vaccines, oncology, immunology, and cardiovascular & metabolic conditions. The focus in Beerse is primarily on research in the first three areas. In addition, there is the new Janssen Global Public Health Group which was established in August of 2013 and which strives, in a sustainable manner, to increase accessibility to medicines against infectious diseases such as AIDS, tuberculosis and neglected tropical diseases in areas with little means but great medical needs.
The two pharmaceutical factories in Beerse mainly specialize in the production of liquid and semi-solid drug formulations. Like the chemical production plants in Geel, they form part of the Global Supply Chain organization, which plays a central role in worldwide supply logistics. Our aim is to make reliable drugs quickly and efficiently available to the patients who need them, anywhere in the world.
Last but not least, there are also a number of support services based in Beerse, which are mainly active locally or internationally. They strengthen the importance of the campus as a crucial link in the worldwide network of companies.
The Beerse 2 site houses the financial sister company JC General Services CVBA, worldwide computer support and the marketing and sales organization Janssen-Cilag NV.
At the beginning of 2012, the completely renovated Johnson & Johnson building in Diegem was reopened. This building houses the Johnson & Johnson headquarters functions in Europe, such as Legal Affairs, Governmental Relations, Corporate Social Responsibility Europe and Logistics.
Within just a few decades, J&J Supply Chain Geel has developed into one of the most innovative and successful chemical production centers in the world. Within the world-wide J&J Supply Chain, the site in Geel is the only launch and growth site for the production of active pharmaceutical ingredients (API’s). These ingredients are then further processed in the pharmaceutical production plants in Beerse or abroad. The site houses high-technology installations, including those for hydrogenation and bromination. The environmentally friendly Chemical Development Pilot Plant (CDPP) plays a key role in this global development and production network.
A specialized plant for the production of medicines in the form of pellets has been operational in Olen since 1992.
In October 2012, Janssen opened the new European Distribution Center for medicines in La Louvière. The Center is part of the distribution network of the worldwide Johnson & Johnson group, and will be the major hub in the distribution of innovative Janssen medicines to patients throughout Europe and some other countries beyond.
Jan Palfijn Hospital in Merksem houses a clinical research unit specifically dedicated to Phase I clinical research (with healthy volunteers).